Study to Evaluate Safety and Efficacy of Early Calcineurin Inhibitor Withdrawal in Primary Renal Allografts
Open Label Randomized Single Study to Evaluate the Safety & Efficacy of Early CNI Withdrawal in Recipients of Primary Renal Allografts Maintained Long-Term on Mycophenolate Mofetil; MMF (CellCept) and Sirolimus (Rapamune)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Ohio
-
Cincinnati, Ohio, United States, 45267
- University of Cincinnati
-
Cincinnati, Ohio, United States, 45267
- The Christ Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and female patients between 18 and 75 years of age.
- Patients who are 90 to 240 days after having received a primary living or cadaver renal allograft.
- Patients maintained on a regimen of cyclosporine or tacrolimus and MMF since transplantation.
- Capable of providing written informed consent.
- No known contraindications to treatment with sirolimus.
Exclusion Criteria:
- Pregnant or lactating.
- Acute rejection within 90 days prior to study randomization.
- More than one biopsy proven acute rejection episode prior to study randomization.
- Previously received or are receiving an organ transplant other than kidney.
- Receiving sirolimus prior to entry.
- Severe diarrhea or other gastrointestinal disorders that may interfere with their ability to absorb oral medication.
- Evidence of active systemic infection requiring antibiotics, or HIV, HCV, HBV infection.
- History of malignancy in the past 5 years.
- Require dialysis at the time of study entry.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
|---|
|
Composite endpoint of either acute rejection, biopsy proven calcineurin inhibitor toxicity, or failure of the estimated BSA indexed GFR by MDRD method to improve by 20% from time randomization to 12 months.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
|---|
|
Renal allograft function at 6 and 12 months.
|
|
Incidence of biopsy proven acute rejection at 6 and 12 months.
|
|
Time to first rejection.
|
|
Total number of rejection episodes per patient.
|
|
Graft loss and patient death.
|
|
Incidence of treatment failure.
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Anti-Bacterial Agents
- Antibiotics, Antineoplastic
- Antifungal Agents
- Antitubercular Agents
- Antibiotics, Antitubercular
- Mycophenolic Acid
- Sirolimus
Other Study ID Numbers
Other Study ID Numbers
- STN INV INT
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.